GSC The List

Post Reply
Forum Home > P > PARKINSON'S DISEASE*+

[email protected]
Site Owner
Posts: 1174

Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders (full – 2010) http/ onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2010.00144.x/full

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC2848893/?toolubmed

Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. (full – 2010) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3659808/

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010) http/www.mdpi.com/1424-8247/3/8/2689

Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3145842/?toolubmed

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/

Prospects for cannabinoid therapies in basal ganglia disorders. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3165947/

Symptom-relieving and neuroprotective effects of the phytocannabinoid D(9) -THCV in animal models of Parkinson's disease (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3165958/pdf/bph0163-1495.pdf

Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation. (full – 2011) http/www.jimmunol.org/content/187/12/6508.full?sid=c3422dd2-7ad0-42e4-a862-845dc670f7cf

Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3165948/

Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation (full – 2011) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3249428/

Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinson's Disease (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21568925/abstract/Therapeutic_Potential_of_Cannabinoids_in_the_Treatment_of_Neuroinflammation_Associated_with_Parkinson%27s_Disease_

Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21459482/abstract/Regional_changes_in_type_1_cannabinoid_receptor_availability_in_Parkinson%27s_disease_in_vivo_

Homeostatic changes of the endocannabinoid system in Parkinson's disease. (abst – 2011) http/www.unboundmedicine.com/medline/ebm/record/21412829/abstract/Homeostatic_changes_of_the_endocannabinoid_system_in_Parkinson%27s_disease_

New metabolic pathway for controlling brain inflammation (news – 2011) http/www.news-medical.net/news/20111021/New-metabolic-pathway-for-controlling-braininflammation.aspx

Scripps Research Scientists Discover Inflammation Is Controlled Differently in Brain and Other Tissues (news – 2011) http/www.alphagalileo.org/ViewItem.aspx?ItemId=113766&CultureCode=en

The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full - 2012) http/onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02175.x/full

The Therapeutic Potential of Cannabis and Cannabinoids (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3442177/

Cannabinoid modulation of neuroinflammatory disorders. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3386505/

Review article: The endocannabinoid system in normal and pathological brain ageing (full – 2012) http/rstb.royalsocietypublishing.org/content/367/1607/3326.full?sid=161e7b36-5055-448b-962e-697c782e901d

The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3273613/

Cannabinoids and value-based decision making: implications for neurodegenerative disorders. (full – 2012) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3496267/

Δ(9) -THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22236282

The decrease of dopamine D(2)/D(3) receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB(1) cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D(2)/D(3) antagonist [(3)H]raclopride and the novel CB(1) inverse agonist [(125)I]SD7015. (abst – 2012) http/www.ncbi.nlm.nih.gov/pubmed/22421165

Contribution of genetic variants to pain susceptibility in Parkinson disease (abst – 2012) http/onlinelibrary.wiley.com/doi/10.1002/j.1532-2149.2012.00134.x/abstract

Scientists find a new pharmacological target to modulate the effect of cannabinoids through their CB1 receptors (news – 2012) http/www.alphagalileo.org/ViewItem.aspx?ItemId=122183&CultureCode=en

5 Marijuana Compounds That Could Help Combat Cancer, Alzheimers, Parkinsons (If Only They Were Legal) (news – 2012) http/www.alternet.org/drugs/5-marijuana-compounds-could-help-combat-cancer-alzheimers-parkinsonsif-only-they-were-legal

Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy. (full – 2013) http/iospress.metapress.com/content/4j61942x88175321/fulltext.html

Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine. (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3730975/

Striatal Molecular Signature of Subchronic Subthalamic Nucleus High Frequency Stimulation in Parkinsonian Rat. (full – 2013) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC3617149/

The Influence of Cannabinoids on Generic Traits of Neurodegeneration. (full – 2013) http/onlinelibrary.wiley.com/doi/10.1111/bph.12492/full

A spontaneous deletion of α-Synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: Effects on alcohol consumption (abst – 2013) http/onlinelibrary.wiley.com/doi/10.1002/syn.21639/abstract

Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptors activation in mice. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23791616

Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23829360

Δ9-Tetrahydrocannabinol is protective through PPARγ dependent mitochondrial biogenesis in a cell culture model of Parkinson’s Disease (abst – 2013) http/jnnp.bmj.com/content/84/11/e2.58.abstract

Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24140894

The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/24196024

Cannabidiol Normalizes Capase 3, Synatophsin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection (abst – 2013) http/www.ncbi.nlm.nih.gov/pubmed/23893294

Smoking Pot Eases Tremors in Parkinson's (news – 2013) http/www.medpagetoday.com/MeetingCoverage/MDS/39933

The endocannabinoid system: a putative role in neurodegenerative diseases. (full – 2014) http/www.ncbi.nlm.nih.gov/pmc/articles/PMC4070159/

L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24412491

Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24599755

Cannabis (Medical Marijuana) Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: An Open-Label Observational Study. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24614667

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24845114

The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24973119

Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. (abst – 2014) http/www.ncbi.nlm.nih.gov/pubmed/24972960

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25237116

Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25481767

Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/25486547

March 19, 2015 at 7:57 AM Flag Quote & Reply

This topic is closed, no additional posts are allowed.